Opinion|Videos|August 30, 2024
Biomarkers as Tools in Management of Type 2 Inflammation
Author(s)Reynold A. Panettieri Jr, MD
An expert in COPD delves into biomarkers indicative of type 2 inflammation and recommends diagnostic tests for assessing inflammation in COPD patients.
Advertisement
Episodes in this series
- What biomarkers can reliably assess the presence of type 2 inflammation as a contributing factor in asthma or COPD?
- How can absolute eosinophil count specifically be used as a tool in this population for regimen selection? Does this biomarker have a role in predicting treatment response or patient outcomes?
Advertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
A post hoc ASPEN analysis links darker sputum to higher protease activity in bronchiectasis.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Disability, Economic Toll of Multimorbidity Climb in Older Adults
3
FAQ: PBM Reform, 340B, and Medicare Shifts Payers Face in 2027
4
October FDA Approvals Bring Advances Across 5 Specialties
5